Immix Biopharma Awarded European Union Orphan Drug
European Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EUAccess to the ...
Read moreEuropean Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EUAccess to the ...
Read moreARCA biopharma and Oruka Therapeutics announce Merger AgreementARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE ...
Read moreUpdated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory AL amyloidosis will be presented in Baltimore May 7-11, 2024 LOS ...
Read moreIpsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completing the final stages of pre-clinical ...
Read moreIRVINE, Calif., March 30, 2024 (GLOBE NEWSWIRE) -- Regarding a release issued under the same headline on March 29, 2024 ...
Read moreCompany progresses the development of furmonertinib with a data readout planned for 2024Furmonertinib granted Breakthrough Therapy Designation by the U.S. ...
Read more– Recent end-of-Phase 2 meeting with FDA resulted in alignment on the design and endpoints for the proposed pivotal Phase ...
Read moreIRVINE, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON; AEON.WS) (“AEON” or “the Company”), a clinical-stage ...
Read more-- Termination of the Forward Purchase Agreements simplifies AEON’s capitalization structure -- -- AEON to expand its Board of Directors ...
Read more– FDA and AEON align on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.